PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?

J Thorac Oncol. 2019 Aug;14(8):1323-1326. doi: 10.1016/j.jtho.2019.05.004.

Authors

Carl M Gay¹, Lauren A Byers²

Affiliations

¹ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
² Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Electronic address: lbyers@mdanderson.org.

PMID: 31345330
DOI: 10.1016/j.jtho.2019.05.004

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal
Humans
Lung Neoplasms*
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors*

Substances

Antibodies, Monoclonal
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
durvalumab
olaparib